GoodRx shares rose 1.5% in premarket trading Tuesday after the healthcare company said it will offer a 30-day supply of oral ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., ...

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

“Following the recently announced positive news of the QSYMIA label update, which removed strict requirements of BMI for patient eligibility, we are thrilled to receive this response from the ...

Collaborative telehealth platform will provide patients with immediate access to QSYMIA ®, a chronic weight loss medication, enhancing their healthcare journey CAMPBELL, Calif., Oct. 30 ...

By making QSYMIA more accessible, GoodRx and Vivus are helping those struggling with weight and obesity find more affordable ways to access the treatments they need. Now, anyone with a valid ...

Investing.com -- GoodRx shares rose 1.5% in premarket trading Tuesday after the healthcare company said it will offer a 30-day supply of oral weight management drug Qsymia for $149. The stock lost ...

CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its ...

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules CIV) is available for a low cash ...